Health and Economic Impact Analysis of Uncontrolled Hemophilia Patients in Colombia
Author(s)
DAYSI SANMARTIN DURANGO, Econ, MSc1, María Alejandra Barrios-Mercado, MD, MSc1, Juan Sebastian Salazar, Econ1, Daniel Casas-Ramirez, Sr., Econ, MSc2, Alexander Moreno-Calderón, PhD2.
1Sapyens SAS BIC, Bogota, Colombia, 2Novo Nordisk, Bogota, Colombia.
1Sapyens SAS BIC, Bogota, Colombia, 2Novo Nordisk, Bogota, Colombia.
OBJECTIVES: Given the recent changes in the Colombian healthcare system, evidence is required to support decision-making processes aimed at financial sustainability. This is particularly relevant for orphan diseases. The objective of this study was to estimate the health and economic impact of uncontrolled haemophilia A and B patients in Colombia.
METHODS: A budget impact analysis from a health system perspective was conducted to evaluate the annual clinical and economic burden of adult and paediatric patients with uncontrolled haemophilia, including haemophilia A and B with and without inhibitors. Epidemiological data were obtained from the Colombian High-Cost Disease Registry (Cuenta de Alto Costo, CAC). Clinical data on annual bleeding rates, haemophilic arthropathy, and knee replacement surgery were extracted from a systematic literature review in MEDLINE and Embase. Costs were calculated using public databases from the Colombian Ministry of Health (for 2023) and the case-type approach, based on treatment protocols from the World Federation of Haemophilia, the CAC, and input from clinical experts. Scenario analyses were implemented.
RESULTS: The prophylactic treatment annual cost for a patient with haemophilia with inhibitors ranged from USD 336,333 to USD 488,298. For patients without inhibitors, the average annual cost of prophylaxis was estimated at USD 76,737. The minimum incremental annual cost of an uncontrolled haemophilia patient ranged from USD 24,153 to USD 29,581.
CONCLUSIONS: Uncontrolled haemophilia can impact patients through increased bleeding episodes, joint deterioration, development of haemophilic arthropathy, and the need for knee replacement surgery, all of which impair their quality of life. Moreover, the lack of control imposes an economic burden on the healthcare system, underscoring the importance of effective management strategies for these patients.
METHODS: A budget impact analysis from a health system perspective was conducted to evaluate the annual clinical and economic burden of adult and paediatric patients with uncontrolled haemophilia, including haemophilia A and B with and without inhibitors. Epidemiological data were obtained from the Colombian High-Cost Disease Registry (Cuenta de Alto Costo, CAC). Clinical data on annual bleeding rates, haemophilic arthropathy, and knee replacement surgery were extracted from a systematic literature review in MEDLINE and Embase. Costs were calculated using public databases from the Colombian Ministry of Health (for 2023) and the case-type approach, based on treatment protocols from the World Federation of Haemophilia, the CAC, and input from clinical experts. Scenario analyses were implemented.
RESULTS: The prophylactic treatment annual cost for a patient with haemophilia with inhibitors ranged from USD 336,333 to USD 488,298. For patients without inhibitors, the average annual cost of prophylaxis was estimated at USD 76,737. The minimum incremental annual cost of an uncontrolled haemophilia patient ranged from USD 24,153 to USD 29,581.
CONCLUSIONS: Uncontrolled haemophilia can impact patients through increased bleeding episodes, joint deterioration, development of haemophilic arthropathy, and the need for knee replacement surgery, all of which impair their quality of life. Moreover, the lack of control imposes an economic burden on the healthcare system, underscoring the importance of effective management strategies for these patients.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE216
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
SDC: Rare & Orphan Diseases